Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy

Shenthol Sasankan; Lorraine Rebuck; Gloria Darrah; Moises Harari Turquie; Ian Rabinowitz

doi:10.1159/000510096

Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy

Case Rep Oncol. 2020 Oct 13;13(3):1239-1243. doi: 10.1159/000510096. eCollection 2020 Sep-Dec.

Authors

Shenthol Sasankan¹, Lorraine Rebuck¹, Gloria Darrah¹, Moises Harari Turquie¹, Ian Rabinowitz¹

Affiliation

¹ Hematology and Medical Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, USA.

Abstract

We report on the clinical history of a 49-year-old female with metastatic pancreatic cancer. She was initially treated with standard chemotherapy as per current guidelines. She was found to have both a BRAF and P53 mutation, and received dabrafenib and trametinib with deep responses, both radiographically and biochemically (CA19-9). Her response has been more clinically relevant than responses in previous case reports of patients with BRAF-positive pancreatic cancer treated with targeted therapy. To the best of our knowledge, this is the first case report showing a dramatic therapeutic response to combination therapy with dabrafenib and trametinib in metastatic pancreatic cancer.

Keywords: BRAF mutation; Cancer biology; Gastrointestinal oncology; Pancreatic cancer; Targeted therapy.

Publication types

Case Reports